Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Annual Estimates of Influenza Vaccine Effectiveness for Preventing Laboratory Confirmed Influenza in the United States, Funding Opportunity Announcement (FOA) IP08-00101SUPP10, Initial Review, 47262 [E9-22154]

Download as PDF 47262 Federal Register / Vol. 74, No. 177 / Tuesday, September 15, 2009 / Notices Time: 1 p.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call) Contact Person: Atul Sahai, PhD., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes Of Health, Room 759, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–2242, sahaia@niddk.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) both CDC and the Agency for Toxic Substances and Disease Registry. Dated: September 9, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–22213 Filed 9–14–09; 8:45 am] Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Annual Estimates of Influenza Vaccine Effectiveness for Preventing Laboratory Confirmed Influenza in the United States, Funding Opportunity Announcement (FOA) IP08– 00101SUPP10, Initial Review sroberts on DSKD5P82C1PROD with NOTICES In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting. Time and Date: 10 a.m.–11 a.m., September 25, 2009 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters To Be Discussed: The meeting will include the initial review, discussion, and evaluation of ‘‘Annual Estimates of Influenza Vaccine Effectiveness for Preventing Laboratory Confirmed Influenza in the United States, FOA IP08–00101SUPP10.’’ Contact Person for More Information: Gregory Anderson, M.P.H., M.S., CDC, 1600 Clifton Road, NE., Mailstop E60, Atlanta, GA 30333, Telephone: (404) 498–2275. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for VerDate Nov<24>2008 19:12 Sep 14, 2009 Jkt 217001 Dated: September 4, 2009. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E9–22154 Filed 9–14–09; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center For Scientific Review; Notice of Closed Meetings Name of Committee: Center for Scientific Review Special Emphasis Panel; HESC Challenge Grant Review. Date: September 24–25, 2009. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Renaissance Mayflower Hotel, 1127 Connecticut Avenue, NW., Washington, DC 20036. Contact Person: Sherry L. Dupere, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5136, MSC 7843, Bethesda, MD 20892, (301) 435– 1021, duperes@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Surgical Sciences, Biomedical Imaging and Bioengineering Integrated Review Group; Surgery, Anesthesiology and Trauma Study Section. Date: September 30–October 1, 2009. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Holiday Inn Georgetown, 2101 Wisconsin Avenue, NW., Washington, DC 20007. Contact Person: Weihua Luo, MD, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5114, MSC 7854, Bethesda, MD 20892, (301) 435– 1170, luow@csr.nih.gov. PO 00000 Frm 00078 Fmt 4703 Sfmt 4703 Name of Committee: Center for Scientific Review, Special Emphasis Panel; Hematology. Date: September 30, 2009. Time: 1 p.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Ai-Ping Zou, MD, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4118, MSC 7814, Bethesda, MD 20892, 301–435– 1777, zouai@csr.nih.gov. Name of Committee: Oncology 2— Translational Clinical Integrated Review Group; Cancer Biomarkers Study Section. Date: October 1–2, 2009. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Avenue Hotel Chicago, 160 E. Huron Street, Chicago, IL 60611. Contact Person: Lawrence Ka-Yun Ng, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6152, MSC 7804, Bethesda, MD 20892, 301–435– 1719, ngkl@csr.nih.gov. Name of Committee: Oncology 1–Basic Translational Integrated Review Group; Molecular Oncogenesis Study Section. Date: October 1–2, 2009. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Avenue Hotel Chicago, 160 E. Huron Street, Chicago, IL 60611. Contact Person: Nywana Sizemore, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6204, MSC 7804, Bethesda, MD 20892, 301–435– 1718, sizemoren@csr.nih.gov. Name of Committee: Oncology 2— Translational Clinical Integrated Review Group; Chemo/Dietary Prevention Study Section. Date: October 1–2, 2009. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hotel Nikko, 222 Mason Street, San Francisco, CA 94102. Contact Person: Sally A. Mulhern, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6214, MSC 7804, Bethesda, MD 20892, (301) 435– 5877, mulherns@csr.nih.gov. Name of Committee: Population Sciences and Epidemiology Integrated Review Group; Social Sciences and Population Studies Study Section. Date: October 1, 2009. Time: 8 a.m. to 7 p.m. Agenda: To review and evaluate grant applications. Place: Amalfi Hotel, 20 West Kinzie Street, Chicago, IL 60654. Contact Person: Bob Weller, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of E:\FR\FM\15SEN1.SGM 15SEN1

Agencies

[Federal Register Volume 74, Number 177 (Tuesday, September 15, 2009)]
[Notices]
[Page 47262]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-22154]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP): Annual Estimates of Influenza Vaccine 
Effectiveness for Preventing Laboratory Confirmed Influenza in the 
United States, Funding Opportunity Announcement (FOA) IP08-00101SUPP10, 
Initial Review

    In accordance with Section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the aforementioned meeting.

    Time and Date: 10 a.m.-11 a.m., September 25, 2009 (Closed).
    Place: Teleconference.
    Status: The meeting will be closed to the public in accordance 
with provisions set forth in Section 552b(c) (4) and (6), Title 5 
U.S.C., and the Determination of the Director, Management Analysis 
and Services Office, CDC, pursuant to Public Law 92-463.
    Matters To Be Discussed: The meeting will include the initial 
review, discussion, and evaluation of ``Annual Estimates of 
Influenza Vaccine Effectiveness for Preventing Laboratory Confirmed 
Influenza in the United States, FOA IP08-00101SUPP10.''
    Contact Person for More Information: Gregory Anderson, M.P.H., 
M.S., CDC, 1600 Clifton Road, NE., Mailstop E60, Atlanta, GA 30333, 
Telephone: (404) 498-2275.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining 
to announcements of meetings and other committee management 
activities, for both CDC and the Agency for Toxic Substances and 
Disease Registry.

    Dated: September 4, 2009.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. E9-22154 Filed 9-14-09; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.